Skip to content

AbCellera Biologics Inc.

ABCL

CIK 0001703057 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$38.59M
+160.6% YoY Q1 May 2026
Net Income (TTM)
−$180.63M
+10.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.60
+10.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-637.6%
Q1 May 2026
Net Margin
-468.1%
Q1 May 2026
Free Cash Flow (TTM)
−$184.44M
Q1 May 2026
Cash
$77.06M
Q1 May 2026
Total Debt
$190K
Q1 May 2026
Shares Outstanding
305.38M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings